Mendez-Lizarraga Cesar A, Chacon-Cruz Enrique, Carrillo-Meza Ricardo, Hernández-Milán Néstor Saúl, Inustroza-Sánchez Leslie C, Ovalle-Marroquín Diego F, Machado-Contreras Jesús René, Ceballos Zuñiga Omar, Bejarano-Ramírez Verónica, Aguilar-Aguayo Cipriano, Medina-Amarillas Adrián, Ceballos-Liceaga Santa Elizabeth, Zazueta Oscar E
Departamento de Epidemiología, Secretaría de Salud de Baja California, Mexicali 21000, Mexico.
Departamento de Infectología Pediátrica, Hospital General de Tijuana, Tijuana 22000, Mexico.
Vaccines (Basel). 2022 Jul 27;10(8):1196. doi: 10.3390/vaccines10081196.
After emergency authorization, different COVID-19 vaccines were administered across Mexico in 2021, including mRNA, viral vector, and inactivated platform vaccines. In the state of Baja-California, 3,516,394 doses were administered, and 2285 adverse events (AE) were registered in the epidemiological surveillance system in 2021. Incidence rates per 100,000 doses were calculated for total, mild (local and systemic), and severe AE for each vaccine. Symptoms were compared between mRNA and viral vector/inactivated virus vaccines. The overall incidence rate for all AE was 64.98 per 100,000 administered doses; 79.05 AE per 100,000 doses for mRNA vaccines; and 56.9 AE per 100,000 doses for viral vector/inactivated virus vaccine platforms. AE were at least five times higher in recipients of the AstraZeneca vaccine from the Serum Institute of India (AZ from SII). Local injection site symptoms were more common in mRNA vaccines while systemic were more prevalent in viral vector/inactivated virus vaccines. Severe AE rates were similar across all administered vaccines (0.72-1.61 AE per 100,000 doses), except for AZ from SII, which documented 12.6 AE per 100,000 doses. Among 32 hospitalized severe cases, 28 (87.5%) were discharged. Guillain-Barré Syndrome was the most common serious AE reported ( = 7). Adverse events rates differed among vaccine manufacturers but were consistent with clinical trials and population-based reports in the literature.
在紧急授权之后，2021年墨西哥各地接种了不同的新冠疫苗，包括信使核糖核酸（mRNA）疫苗、病毒载体疫苗和灭活疫苗平台。在南下加利福尼亚州，2021年共接种了3516394剂疫苗，流行病学监测系统记录了2285起不良事件（AE）。计算了每种疫苗每10万剂的总不良事件、轻度不良事件（局部和全身）以及严重不良事件的发生率。对mRNA疫苗与病毒载体/灭活病毒疫苗的症状进行了比较。所有不良事件的总体发生率为每10万剂接种量64.98起；mRNA疫苗每10万剂的不良事件发生率为79.05起；病毒载体/灭活病毒疫苗平台每10万剂的不良事件发生率为56.9起。来自印度血清研究所的阿斯利康疫苗（印度血清研究所生产的阿斯利康疫苗，简称AZ from SII）接种者的不良事件发生率至少高出五倍。局部注射部位症状在mRNA疫苗中更为常见，而全身症状在病毒载体/灭活病毒疫苗中更为普遍。除了印度血清研究所生产的阿斯利康疫苗每10万剂记录有12.6起不良事件外，所有接种疫苗的严重不良事件发生率相似（每10万剂0.72 - 1.61起不良事件）。在32例住院的严重病例中，28例（87.5%）已出院。格林 - 巴利综合征是报告的最常见严重不良事件（ = 7）。不同疫苗生产商的不良事件发生率有所不同，但与文献中的临床试验和基于人群的报告一致。
